Cargando…
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
Background: Anti-CD20 B cell depleting agents are amongst the most commonly used immunotherapeutics employed in the treatment of haematological malignancy and autoimmune diseases. By inducing peripheral B cell aplasia, anti-CD20 depleting agents are hypothesised to significantly impair serological r...
Autores principales: | Shields, Adrian M, Venkatachalam, Srinivasan, Paneesha, Shankara, Ford, Mark, Sheeran, Tom, Kelly, Melanie, Karim, Farheen, Qureshi, Iman, Salhan, Beena, DeSilva, Neelakshi, Stones, Jacqueline, Lee, Sophie, Khawaja, Jahanzeb, Kaudlay, Praveen Kumar, Whitmill, Richard, Nabikakepoto, Ghulam, Faustini, Sian E, Richter, Alex G, Drayson, Mark T, Basu, Supratik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701526/ http://dx.doi.org/10.1182/blood-2021-150220 |
Ejemplares similares
-
A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity
por: Wu, Jianghua, et al.
Publicado: (2021) -
Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19
por: Corona De Lapuerta, Magdalena, et al.
Publicado: (2021) -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
por: Shree, Tanaya, et al.
Publicado: (2021) -
Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial
por: Charania, Asad, et al.
Publicado: (2021) -
Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections
por: Singh, Aditi, et al.
Publicado: (2021)